Figure 3
Figure 3. Proinflammatory tachykinins prevent apoptosis of BMDCs by NK1R signaling. (A) Comparison of the antiapoptotic effects of SarSP, SP, and HK-1 at physiological (10−9 mol/L) and nonphysiological (10−5 mol/L) concentrations on CD11c+ BMDCs as determined by FACS analysis of annexin V and PI labeling. (B,C) Bar-diagrams representing the antiapoptotic effect of SarSP on CD11c+ BMDCs is abrogated by (B) preincubation with the highly selective NK1R antagonist WIN-51708 or (C) in NK1R−/−KO BMDCs. ***P < .001. (A-C) Means (± SD) of 3 independent experiments are illustrated. (D) Dot-plots illustrating the percentage of apoptosis (numbers in dot-plots) of CD11c+ BMDCs signaled with NK1R antagonist WIN-51708 alone. Data are representative of 4 independent experiments.

Proinflammatory tachykinins prevent apoptosis of BMDCs by NK1R signaling. (A) Comparison of the antiapoptotic effects of SarSP, SP, and HK-1 at physiological (10−9 mol/L) and nonphysiological (10−5 mol/L) concentrations on CD11c+ BMDCs as determined by FACS analysis of annexin V and PI labeling. (B,C) Bar-diagrams representing the antiapoptotic effect of SarSP on CD11c+ BMDCs is abrogated by (B) preincubation with the highly selective NK1R antagonist WIN-51708 or (C) in NK1R−/−KO BMDCs. ***P < .001. (A-C) Means (± SD) of 3 independent experiments are illustrated. (D) Dot-plots illustrating the percentage of apoptosis (numbers in dot-plots) of CD11c+ BMDCs signaled with NK1R antagonist WIN-51708 alone. Data are representative of 4 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal